78 - Antimicrobial Clinical Trials (Bacterial & Viral)

Moderator(s)

• 

  Pranita Tamma, MD, MHS

  Associate Professor
  Johns Hopkins School of Medicine
  Baltimore, Maryland, United States

  Disclosure(s): No financial relationships to disclose
• 

  Jason Gallagher, PharmD

  Clinical Professor
  Temple University School of Pharmacy
  Philadelphia, PA, United States

  Disclosure(s): Merck and Company, Inc.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing), Honoraria (Ongoing); Qpex Biopharma: Advisor/Consultant (Ongoing), Honoraria (Ongoing); Shionogi & Co.,Ltd.: Advisor/Consultant (Ongoing), Honoraria (Ongoing)

No CE Credit Offered

Presentations:

• 1:45 PM – 2:00 PM US ET

  A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ridinilazole Compared with Vancomycin for the Treatment of Clostridioides difficile Infection
  

  Presenting Author: Pablo C. Okhuysen, MD – The University of Texas MD Anderson Cancer Center

  Co-Author: Mayur Ramesh, MD – Henry Ford Hospital

  Co-Author: Kevin W. Garey, PharmD, MS (he/him/his) – University of Houston

  Co-Author: Thomas J. Louie, MD – University of Calgary

  Co-Author: Julian Torre Cisneros, Md, Ph.D – Hospital Universitario Reina Sofia

  Co-Author: Alena Stychneuskaya, n/a – Vitebsk regional hospital of infection deseases

  Co-Author: Nino Kiknadze, n/a – Aversi Clinic Ltd

  Co-Author: Jianling LI, MS – Summit Therapeutics

  Co-Author: Esther Duperchy, PhD – Summit Plc

  Co-Author: Professor Mark H. Wilcox, MD, FRCPath – University of Leeds; Leeds Teaching Hospitals NHS Trust

  Co-Author: Jose G. Montoya, MD – Dr. Jack S. Remington Laboratory for Specialty Diagnostics

  Co-Author: Lori Styles, MD – Summit Therapeutics

  Co-Author: Fong Clow, Sc. D – Summit Therapeutics

  Co-Author: Danelle James, MD – Summit Therapeutics

  Co-Author: Erik R. Dubberke, MD, MSPH – Washington University

  Co-Author: Claudia M. De Oliveira, MD – Santa Casa de Belo Horizonte

  Co-Author: Christophe Van Steenkiste, MD, PhD – Az Maria Middelares Ghent / University Antwerp
• 2:00 PM – 2:15 PM US ET

  CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)
  

  Presenting Author: Paul C. McGovern, MD – Venatorx Pharmaceuticals

  Co-Author: Florian Wagenlehner, MD – Justuf Liebeg University Diessen

  Co-Author: Leanne Gasink, MD, MSCE – LBG Consulting

  Co-Author: Greg Moeck, PhD – Venatorx Pharmaceuticals

  Co-Author: Patrick L. McLeroth, MD – Labcorp

  Co-Author: Mary Beth Dorr, PhD – Venatorx

  Co-Author: Aaron Dane, MSc – Danestat Consulting Limited

  Co-Author: Tim Henkel, MD, PhD – Venatorx Pharmaceuticals
• 2:15 PM – 2:30 PM US ET

  Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections
  

  Presenting Author: David Altarac, MD, MPA – Entasis Therapeutics

  Co-Author: Alita Miller, PhD – Entasis Therapeutics

  Co-Author: Sarah McLeod, PhD (she/her/hers) – Entasis Therapeutics

  Co-Author: Adam B. Shapiro, Ph.D – Entasis Therapeutics

  Co-Author: Khurram Rana, PharmD – Entasis Therapeutics

  Co-Author: Drew Lewis, MD, MTM&H – Entasis Therapeutics

  Co-Author: Gabrielle Poirier, BS – Entasis Therapeutics

  Co-Author: Daria Chabas, BS – Entasis Therapeutics
• 2:30 PM – 2:45 PM US ET

  Letermovir treatment for refractory or resistant cytomegalovirus infection or disease with concurrent organ dysfunction: an interim analysis of a Phase 2 open label study.
  

  Presenting Author: Isabel H. Gonzalez-Bocco, MD – Brigham and Women's Hospital

  Co-Author: Matthew Cheng, MD – McGill University Health Centre

  Co-Author: Muneerah M. Aleissa, PharmD, MPH – Brigham and Women's Hospital

  Co-Author: Esther I. Arbona, N/A, MD – BWH

  Co-Author: Kaiwen Chen, BS/BA – Robert Wood Johnson Medical School

  Co-Author: Eric Zhou, BA – BWH

  Co-Author: Katherine Beluch, B.S. – Brigham and Women's Hospital

  Co-Author: Alyssa Cho, n/a – Brigham and Women's Hospital

  Co-Author: Sandra Burchett, MD, MSc – Boston Childrens Hospital/Harvard Medical School

  Co-Author: Sarah P. Hammond, MD – Massachusetts General Hospital

  Co-Author: Nicolas C. Issa, MD – Brigham & Women's Hospital

  Co-Author: Amy C. Sherman, MD – Brigham and Women's Hospital

  Co-Author: Francisco M. Marty, MD, SM – Brigham and Women's Hospital
• 2:45 PM – 3:00 PM US ET

  Efficacy of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with extensively drug-resistant (XDR) and pan-drug resistant (PDR) Acinetobacter baumannii-calcoaceticus complex (ABC) infections
  

  Presenting Author: Alita Miller, PhD – Entasis Therapeutics

  Co-Author: Sarah McLeod, PhD (she/her/hers) – Entasis Therapeutics

  Co-Author: Adam B. Shapiro, Ph.D – Entasis Therapeutics

  Co-Author: Khurram Rana, PharmD – Entasis Therapeutics

  Co-Author: Drew Lewis, MD, MTM&H – Entasis Therapeutics

  Co-Author: Gabrielle Poirier, BS – Entasis Therapeutics

  Co-Author: Daria Chabas, BS – Entasis Therapeutics

  Co-Author: David Altarac, MD, MPA – Entasis Therapeutics